Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain

Abstract Background Respiratory syncytial virus (RSV) is associated with substantial morbidity among infants. This study modelled the potential public health and economic impact of nirsevimab, a long-acting monoclonal antibody, as an immunoprophylactic strategy for all infants in Spain in their firs...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ruth Gil-Prieto, Jaime Jesus Pérez, Georgina Drago, Alexia Kieffer, Julie Roïz, Paulina Kazmierska, Aditya Sardesai, Solène de Boisvilliers, Juan Luis López-Belmonte, Matthieu Beuvelet, Javier Alvarez Aldean
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2024-09-01
Sarja:	BMC Infectious Diseases
Aiheet:	Hospitalisation Immunisation Infant Nirsevimab Public health Respiratory syncytial viruses
Linkit:	https://doi.org/10.1186/s12879-024-09642-0
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!